However, thymoquinone treatment polarized aggressive late-stage cancer cells toward the CD133+ or CD44 + CD133+ phenotype, which strikingly correlated with decreased autophagy in the hypoxic model, suggesting that these markers may play a role in thymoquinone-mediated cytotoxic responses, especially in aggressive cancer cells. Here, PROM1 is linked to cancer.